2024 ENDO 研究表明，使用 teprotumumab 治疗可以持续缓解甲状腺眼病症状，从而减少对其他治疗的需求。 2024 ENDO study shows sustained relief from thyroid eye disease symptoms with teprotumumab treatment, reducing need for additional treatments.

在 ENDO 2024 的一项研究中，大多数接受 teprotumumab 治疗（八次输注）的甲状腺眼病患者的眼球凸出和复视等症状得到持续缓解，并且在近两年后不需要额外治疗。 In a study at ENDO 2024, most patients with thyroid eye disease who received teprotumumab treatment (eight infusions) experienced sustained relief from symptoms like eye bulging and double vision, and did not require additional treatments nearly two years later. 这项研究凸显了甲状腺眼病（一种可能恶化或发作的终身自身免疫性疾病）持久改善的潜力。 The research highlights the potential for lasting improvements in thyroid eye disease, a lifelong autoimmune disease that can worsen or flare.